Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Neurol.

Sec. Dementia and Neurodegenerative Diseases

Trends in Mortality from Alzheimer's Disease and Related Dementias with Hyperlipidemia in the United States from 1999 to 2020 – A CDC WONDER Database Study

Provisionally accepted
Junwen  WangJunwen Wang1Kaide  XiaKaide Xia2Dianmei  YangDianmei Yang3Jing  WuJing Wu1Longfei  LiuLongfei Liu1Ying  HuangYing Huang4Qing  ShanQing Shan3Haiwang  ZhangHaiwang Zhang5*Yiming  WangYiming Wang3*
  • 1Guizhou Medical University, Guiyang, China
  • 2Guiyang Maternity and Child Health Hospital, Guiyang, China
  • 3The Affiliated Hospital of Guizhou Medical University, Guiyang, China
  • 4The Second People's Hospital of Guiyang, Guiyang, China
  • 5Guizhou Provincial People's Hospital, Guiyang, China

The final, formatted version of the article will be published soon.

Background: The co-occurrence of Alzheimer's disease and related dementias (ADRD) with hyperlipidemia represents a growing public health burden amid population aging. Although both conditions have been independently linked to increased morbidity and mortality, national trends in ADRD-related mortality involving hyperlipidemia remain poorly characterized. Methods: We conducted a retrospective, population-based study using mortality data from the U.S. Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) from 1999 to 2020. Deaths with co-listed International Classification of Diseases, Tenth Revision codes for ADRD and hyperlipidemia were identified. Age-standardized mortality rates (ASMR) were calculated per 100,000 persons using the 2000 U.S. standard population. Joinpoint regression was employed to estimate annual percentage change (APC) and average annual percentage change (AAPC) with 95% confidence intervals (CI). Results: Between 1999 and 2020, the number of deaths related to ADRD with hyperlipidemia increased from 519 to 21,969, with the ASMR rising from 0.19 to 5.32 per 100,000 (AAPC: 15.25%; 95% CI: 14.37–17.31). A sharp rise in mortality was observed after 2018 across nearly all subgroups. Males had a steeper increase than females (AAPC: 16.31% vs. 14.97%). Non-Hispanic Black individuals had the highest ASMR in 2020 (5.53 per 100,000), while Asian/Pacific Islanders had the most rapid increase (AAPC: 21.80%). Regionally, the South showed the highest burden, while the Northeast exhibited the fastest growth (AAPC: 17.77%). Rural areas had a higher ASMR than metropolitan areas (6.29 vs. 5.09 per 100,000), with comparable upward trends. Notably, individuals aged ≥85 years accounted for over half of all deaths by 2020 and exhibited the highest age-specific mortality rates. Conclusions: ADRD-related mortality involving hyperlipidemia has significantly risen in the U.S. over two decades, with notable disparities across demographics and geography, underscoring the need for public-health relevance and coordination to be evaluated in future analytic studies targeting cardiometabolic and cognitive health in high-risk populations.

Keywords: Alzheimer's disease and related dementias, Hyperlipidemia, ASMR, CDCWONDER, AAPC

Received: 15 Sep 2025; Accepted: 02 Dec 2025.

Copyright: © 2025 Wang, Xia, Yang, Wu, Liu, Huang, Shan, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Haiwang Zhang
Yiming Wang

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.